Home Tags Aimmune Therapeutics

European Phase 3 Trial of AR101 Peanut OIT Candidate Meets Primary...

News Wire ~ 3rd Party Press Release - 2019/03/25 0

US FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut...

News Wire ~ 3rd Party Press Release - 2019/03/18 0

Aimmune Therapeutics Presents New AR101 Data Including Demonstrated Reduction in Accidental...

News Wire ~ 3rd Party Press Release - 2019/02/25 0

Government Shutdown Delays Review of AR101 Peanut Oral Immunotherapy Candidate

Dave Bloom - 2019/01/16 0

Aimmune Submits FDA Application to Offer AR101 for the Treatment of...

News Wire ~ 3rd Party Press Release - 2018/12/21 0

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

News Wire ~ 3rd Party Press Release - 2018/12/20 0

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

News Wire ~ 3rd Party Press Release - 2018/10/15 0

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Dave Bloom - 2018/09/27 1

European Study Shows Significant Psychosocial Burden Associated with Peanut Allergy

News Wire ~ 3rd Party Press Release - 2018/05/30 0

Peanut OIT Phase 3 Trial Results Show Therapy Effective for Ages...

Dave Bloom - 2018/05/29 0

1...345 Page 4 of 5

Put Your School on the Map

Dave Bloom - 2024/07/31 0

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of Service and Privacy Policy.

Tag: Aimmune Therapeutics